Home > Publications database > A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. > print |
001 | 164298 | ||
005 | 20240229133514.0 | ||
024 | 7 | _ | |a 10.1093/neuonc/noaa251 |2 doi |
024 | 7 | _ | |a pmid:33130881 |2 pmid |
024 | 7 | _ | |a 1522-8517 |2 ISSN |
024 | 7 | _ | |a 1523-5866 |2 ISSN |
024 | 7 | _ | |a altmetric:97530372 |2 altmetric |
037 | _ | _ | |a DKFZ-2020-02381 |
041 | _ | _ | |a eng |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Sievers, Philipp |0 P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6 |b 0 |e First author |
245 | _ | _ | |a A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. |
260 | _ | _ | |a Oxford |c 2021 |b Oxford Univ. Press |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1641315506_11028 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
500 | _ | _ | |a 2021 Jan 30;23(1):34-43 #EA:B360#LA:B300# |
520 | _ | _ | |a Malignant astrocytic gliomas in children show a remarkable biological and clinical diversity. Small in-frame insertions or missense mutations in the EGFR gene have recently been identified in a distinct subset of pediatric-type bithalamic gliomas with a unique DNA methylation pattern.Here, we investigated an epigenetically homogeneous cohort of malignant gliomas (n=58) distinct from other subtypes and enriched for pediatric cases and thalamic location, in comparison with this recently identified subtype of pediatric bithalamic gliomas.EGFR gene amplification was detected in 16/58 (27%) tumors, and missense mutations or small in-frame insertions in EGFR were found in 20/30 tumors with available sequencing data (67%; five of them co-occurring with EGFR amplification). Additionally, eight of the 30 tumors (27%) harbored an H3.1 or H3.3 K27M mutation (six of them with a concomitant EGFR alteration). All tumors tested showed loss of H3K27me3 staining, with evidence of EZHIP overexpression in the H3 wildtype cases. Although some tumors indeed showed a bithalamic growth pattern, a significant proportion of tumors occurred in the unilateral thalamus or in other (predominantly midline) locations.Our findings present a distinct molecular class of pediatric-type malignant gliomas largely overlapping with the recently reported bithalamic gliomas characterized by EGFR alteration, but additionally showing a broader spectrum of EGFR alterations and tumor localization. Global H3K27me3 loss in this group appears to be mediated by either H3 K27 mutation or EZHIP overexpression. EGFR inhibition may represent a potential therapeutic strategy in these highly aggressive gliomas. |
536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
700 | 1 | _ | |a Sill, Martin |0 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b |b 1 |
700 | 1 | _ | |a Schrimpf, Daniel |0 P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc |b 2 |
700 | 1 | _ | |a Stichel, Damian |0 P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17 |b 3 |
700 | 1 | _ | |a Reuß, David |0 P:(DE-He78)d5149ffd74f42a2fa87a086d66645aaa |b 4 |
700 | 1 | _ | |a Sturm, Dominik |0 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807 |b 5 |
700 | 1 | _ | |a Hench, Jürgen |b 6 |
700 | 1 | _ | |a Frank, Stephan |b 7 |
700 | 1 | _ | |a Krskova, Lenka |b 8 |
700 | 1 | _ | |a Vicha, Ales |b 9 |
700 | 1 | _ | |a Zapotocky, Michal |b 10 |
700 | 1 | _ | |a Bison, Brigitte |b 11 |
700 | 1 | _ | |a Castel, David |b 12 |
700 | 1 | _ | |a Grill, Jacques |b 13 |
700 | 1 | _ | |a Debily, Marie-Anne |0 P:(DE-HGF)0 |b 14 |
700 | 1 | _ | |a Harter, Patrick N |0 P:(DE-HGF)0 |b 15 |
700 | 1 | _ | |a Snuderl, Matija |b 16 |
700 | 1 | _ | |a Kramm, Christof M |b 17 |
700 | 1 | _ | |a Reifenberger, Guido |0 P:(DE-HGF)0 |b 18 |
700 | 1 | _ | |a Korshunov, Andrey |0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93 |b 19 |
700 | 1 | _ | |a Jabado, Nada |b 20 |
700 | 1 | _ | |a Wesseling, Pieter |b 21 |
700 | 1 | _ | |a Wick, Wolfgang |0 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee |b 22 |
700 | 1 | _ | |a Solomon, David A |b 23 |
700 | 1 | _ | |a Perry, Arie |b 24 |
700 | 1 | _ | |a Jacques, Thomas S |b 25 |
700 | 1 | _ | |a Jones, Chris |b 26 |
700 | 1 | _ | |a Witt, Olaf |0 P:(DE-He78)143af26de9d57bf624771616318aaf7c |b 27 |
700 | 1 | _ | |a Pfister, Stefan |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 28 |
700 | 1 | _ | |a von Deimling, Andreas |0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144 |b 29 |
700 | 1 | _ | |a Jones, David |0 P:(DE-He78)551bb92841f634070997aa168d818492 |b 30 |e Last author |
700 | 1 | _ | |a Sahm, Felix |0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88 |b 31 |e Last author |
773 | _ | _ | |a 10.1093/neuonc/noaa251 |g p. noaa251 |0 PERI:(DE-600)2094060-9 |n 1 |p 34-43 |t Neuro-Oncology |v 23 |y 2021 |x 1523-5866 |
909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:164298 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)d5149ffd74f42a2fa87a086d66645aaa |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-HGF)0 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-HGF)0 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-HGF)0 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 19 |6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 22 |6 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 27 |6 P:(DE-He78)143af26de9d57bf624771616318aaf7c |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 28 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 29 |6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 30 |6 P:(DE-He78)551bb92841f634070997aa168d818492 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 31 |6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88 |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
913 | 0 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Functional and structural genomics |x 0 |
914 | 1 | _ | |y 2021 |
915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2020-01-17 |w ger |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2020-01-17 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |d 2020-01-17 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2020-01-17 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2020-01-17 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2020-01-17 |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |d 2020-01-17 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2020-01-17 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-01-17 |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2018 |d 2020-01-17 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2020-01-17 |
915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b NEURO-ONCOLOGY : 2018 |d 2020-01-17 |
920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 0 |
920 | 1 | _ | |0 I:(DE-He78)ED01-20160331 |k ED01 |l DKTK ED ES zentral |x 1 |
920 | 1 | _ | |0 I:(DE-He78)B300-20160331 |k B300 |l KKE Neuropathologie |x 2 |
920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 3 |
920 | 1 | _ | |0 I:(DE-He78)B320-20160331 |k B320 |l KKE Neuroonkologie |x 4 |
920 | 1 | _ | |0 I:(DE-He78)B360-20160331 |k B360 |l Pediatric Glioma |x 5 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
980 | _ | _ | |a I:(DE-He78)ED01-20160331 |
980 | _ | _ | |a I:(DE-He78)B300-20160331 |
980 | _ | _ | |a I:(DE-He78)B062-20160331 |
980 | _ | _ | |a I:(DE-He78)B320-20160331 |
980 | _ | _ | |a I:(DE-He78)B360-20160331 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|